Novo Nordisk and Sandoz settle Victoza patent suit

Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza (Liraglutide) before the companies were meant to face trial in April.

The two parties submitted a stipulation and proposed order of dismissal to the US District Court for the District of Delaware yesterday, March 22, asking the court to dismiss all proceedings related to Victoza patents.

The patents in suit were US patent numbers 8,114,833 and 9,265,893 which cover “Propylene glycol-containing peptide formulations” and an “injection device”.

In an order handed down today, March 23, the district court judge Colm Connolly ok’d the settlement terminating all claims in the lawsuit.

According to a statement from Novo Nordisk made to Fierce Pharma, this clears Sandoz to launch its generic by June 22, 2024, or “earlier under certain circumstances”.

Novo Nordisk first sued Sandoz in June 2020, claiming that Sandoz’s Abbreviated New Drug Application (ANDA) infringed six of its Victoza patents, four of which were dropped prior to trial.

Several other generics manufacturers attempted to secure their own generics prior to the expiration of the patents. Teva managed to secure a similar settlement agreement to manufacture generic Victoza in December 2023.

That settlement agreement also claimed that under “undisclosed circumstances”  Teva could launch its generic as early as March 2023.

Novo Nordisk also sued Mylan in an attempt to block its planned generic of the diabetes treatment.

LSIPR has approached Novo Nordisk and Sandoz for comment.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.